Skip to main content

Table 2 Echocardiographic structural parameters

From: The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats

 

C (n = 14)

DM (n = 15)

DM + DAPA (n = 13)

p value

BW (g)

574 ± 43

339 ± 31 *

415 ± 30 * #

< 0.001

LVDD (mm)

8.64 ± 0.40

8.40 ± 0.51

8.22 ± 0.55

0.098

LVDD/BW (mm/kg)

14.9 (14.0–16.2)

24.2 (23.1–26.4) *

20.2 (18.6–21.9) *#

< 0.001

LVSD (mm)

4.56 ± 0.45

4.55 ± 0.54

4.60 ± 0.51

0.955

LA (mm)

5.87 ± 0.28

6.10 ± 0.27

5.66 ± 0.39 #

0.004

LA/BW (mm/kg)

10.3 (9.36–10.8)

17.2 (16.4–19.8) *

13.8 (13.0–14.6) *#

< 0.001

LV mass (g)

0.89 ± 0.09

0.80 ± 0.08 *

0.76 ± 0.09 *

0.002

LVMI (g/kg)

1.56 ± 0.18

2.36 ± 0.32 *

1.84 ± 0.24 *#

< 0.001

DPWT (mm)

1.42 (1.39–1.46)

1.36 (1.26–1.42)

1.32 (1.28–1.36)

0.076

RWT

0.32 ± 0.02

0.32 ± 0.03

0.32 ± 0.02

0.681

  1. C: control; DM: diabetes mellitus; DM + DAPA: DM treated with dapagliflozin; n: number of rats; BW: body weight; LVDD and LVSD: left ventricle (LV) diastolic and systolic diameters, respectively; LA: left atrium diameter; LVMI: LV mass index; DPWT: diastolic posterior wall thickness; RWT: relative wall thickness. Data are means ± standard deviation or medians and percentiles. ANOVA and Tukey or Kruskal-Wallis and Dunn; * statistically different from C; # statistically different from DM